We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Expert Opinion / Commentary · January 08, 2020

The Potential Development of PD-L1 as a Biomarker in Advanced Melanoma

Written by
Alexander C. J. van Akkooi MD, PhD
Ari VanderWalde MD, MPH, FACP
Zeynep Eroglu MD


Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading